Back to top
more

AquaBounty Technologies (AQB)

(Delayed Data from NSDQ)

$1.07 USD

1.07
13,203

-0.03 (-2.73%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $1.06 -0.01 (-0.93%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies (AQB) delivered earnings and revenue surprises of 1.12% and 52%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies (AQB) delivered earnings and revenue surprises of -67.74% and 80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies (AQB) delivered earnings and revenue surprises of -7.75% and 4.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Immunome (IMNM) delivered earnings and revenue surprises of 57.50% and 74.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cara (CARA) delivered earnings and revenue surprises of -47.37% and 5.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 94.85% and 454.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 20% and 23.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 11.11% and 12.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 12.50% and 31.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Stock Jumps 8.6%: Will It Continue to Soar?

by Zacks Equity Research

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

AquaBounty Technologies, Inc. (AQB) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 0% and 56.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of -42.86% and -40.37%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

AquaBounty Technologies, Inc. (AQB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of -40.00% and -57.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

Top ETF of December & Its Best Stocks

by Sweta Killa

We have highlighted the best ETF of December and its best performing stocks.

AquaBounty (AQB) Surges: Stock Moves 6.3% Higher

by Zacks Equity Research

AquaBounty (AQB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

AquaBounty Technologies, Inc. (AQB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AquaBounty (AQB) Catches Eye: Stock Jumps 8.9%

by Zacks Equity Research

AquaBounty (AQB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 15.38% and -30.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Will AquaBounty Technologies, Inc. (AQB) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease

by Zacks Equity Research

Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.

AquaBounty Technologies, Inc. (AQB) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes AquaBounty Technologies, Inc. (AQB) a New Strong Buy Stock

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 22.22% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will AquaBounty Technologies, Inc. (AQB) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.